Head to Head Contrast: LENZ Therapeutics (NASDAQ:LENZ) vs. Sunshine Biopharma (NASDAQ:SBFM)

LENZ Therapeutics (NASDAQ:LENZ) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for LENZ Therapeutics and Sunshine Biopharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1	2	4	0	2.43
Sunshine Biopharma	1	1	0	0	1.50

LENZ Therapeutics currently has a consensus target price of $23.00, indicating a potential upside of 597.82%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe LENZ Therapeutics is more favorable than Sunshine Biopharma.

Volatility & Risk

LENZ Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 8.3% of LENZ Therapeutics shares are owned by insiders. Comparatively, 1.7% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares LENZ Therapeutics and Sunshine Biopharma”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09 million	5.42	-$82.13 million	($4.09)	-0.81
Sunshine Biopharma	$36.31 million	0.03	-$5.97 million	($10.15)	-0.02

Sunshine Biopharma has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LENZ Therapeutics and Sunshine Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Sunshine Biopharma	-17.94%	-26.36%	-20.60%

About LENZ Therapeutics

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About Sunshine Biopharma

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.